Literature DB >> 10774549

Coreceptor usage and RANTES sensitivity of non-syncytium-inducing HIV-1 isolates obtained from patients with AIDS.

M Jansson1, E Backström, A Björndal, V Holmberg, P Rossi, E M Fenyö, M Popovic, J Albert, H Wigzell.   

Abstract

OBJECTIVES: The biologic phenotype of HIV-1 primary isolates obtained from approximately 50% of patients who progress to AIDS switches from non-syncytium-inducing (NSI) to syncytium-inducing (SI). We evaluated possible associations between virus coreceptor usage, sensitivity to inhibition by beta-chemokines, and disease progression of patients who continue to yield NSI isolates after developing AIDS. STUDY DESIGN/
METHODS: Sequential virus isolates were analyzed for biologic phenotype using the MT-2 cell assay, for sensitivity to beta-chemokines using RANTES inhibition, and for coreceptor usage using U87.CD4 and GHOST.CD4 cells expressing different chemokine/orphan receptors or donor peripheral blood mononuclear cells (PBMC) defective in CCR5 expression. In addition, the env V3 region was sequenced and the length of the V2 region determined.
RESULTS: All NSI isolates, regardless of patient status at time of isolation, were dependent on CCR5 expression for cell entry. Furthermore, there was no indication of broadened coreceptor usage of NSI isolates obtained from persons with late-stage AIDS. A majority of NSI isolates remained RANTES sensitive; however, virus variants with reduced sensitivity were observed. The V2 lengths and the V3 sequences exhibited no or minor changes at analysis of sequential NSI isolates.
CONCLUSIONS: Our data suggest that NSI isolates obtained from AIDS patients remain CCR5 dependent (ie, R5) and, in many cases, also remain sensitive to RANTES inhibition. However, virus variants with decreased sensitivity to RANTES inhibition may evolve during disease progression, not only as a result of a switch from NSI to SI but also in patients who develop AIDS while continuing to maintain R5 isolates.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10774549

Source DB:  PubMed          Journal:  J Hum Virol        ISSN: 1090-9508


  19 in total

1.  Genetic signatures of HIV-1 envelope-mediated bystander apoptosis.

Authors:  Anjali Joshi; Raphael T C Lee; Jonathan Mohl; Melina Sedano; Wei Xin Khong; Oon Tek Ng; Sebastian Maurer-Stroh; Himanshu Garg
Journal:  J Biol Chem       Date:  2013-11-21       Impact factor: 5.157

2.  An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes.

Authors:  Jasminka Sterjovski; Michael Roche; Melissa J Churchill; Anne Ellett; William Farrugia; Lachlan R Gray; Daniel Cowley; Pantelis Poumbourios; Benhur Lee; Steven L Wesselingh; Anthony L Cunningham; Paul A Ramsland; Paul R Gorry
Journal:  Virology       Date:  2010-06-08       Impact factor: 3.616

3.  Evolution of human immunodeficiency virus type 1 in a patient with cross-reactive neutralizing activity in serum.

Authors:  Marit J van Gils; Diana Edo-Matas; Emma J Bowles; Judith A Burger; Guillaume B Stewart-Jones; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-06-08       Impact factor: 5.103

4.  Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.

Authors:  Maria José Duenas-Decamp; Paul J Peters; Alexander Repik; Thomas Musich; Maria Paz Gonzalez-Perez; Catherine Caron; Richard Brown; Jonathan Ball; Paul R Clapham
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

5.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

6.  Human immunodeficiency virus type 1 primary isolate neutralization resistance is associated with the syncytium-inducing phenotype and lower CD4 cell counts in subtype CRF01_AE-infected patients.

Authors:  Victoria R Polonis; Mark S de Souza; Janice M Darden; Somsak Chantakulkij; Thippawan Chuenchitra; Sorachai Nitayaphan; Arthur E Brown; Merlin L Robb; Deborah L Birx
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  Coevolution of RANTES sensitivity and mode of CCR5 receptor use by human immunodeficiency virus type 1 of the R5 phenotype.

Authors:  Ingrid Karlsson; Liselotte Antonsson; Yu Shi; Monica Oberg; Anders Karlsson; Jan Albert; Björn Olde; Christer Owman; Marianne Jansson; Eva Maria Fenyö
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands.

Authors:  Thomas J Ketas; Shawn E Kuhmann; Ashley Palmer; Juan Zurita; Weijing He; Sunil K Ahuja; Per Johan Klasse; John P Moore
Journal:  Virology       Date:  2007-04-10       Impact factor: 3.616

Review 9.  How HIV changes its tropism: evolution and adaptation?

Authors:  Donald E Mosier
Journal:  Curr Opin HIV AIDS       Date:  2009-03       Impact factor: 4.283

10.  HIV-1 subtype CRF01_AE and B differ in utilization of low levels of CCR5, Maraviroc susceptibility and potential N-glycosylation sites.

Authors:  Anjali Joshi; Emily K Cox; Melina J Sedano; Erin B Punke; Raphael Tc Lee; Sebastian Maurer-Stroh; Palvinder Kaur; Oon Tek Ng; Himanshu Garg
Journal:  Virology       Date:  2017-10-09       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.